1-9 of 9
Jakub Krejcik
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group

Diana Loigom, Tobias S. S. Slørdahl, Anna Lysén, Agoston Gyula Szabo, Tine Rosenberg, Lene Kongsgaard Nielsen, Jakub Krejcik, Anne Marit Sponaas, Kristine Misund, Nicolai Jacob Wewer Albrechtsen, Jakob Nordberg Nørgaard, Thomas Lund, Sarah Leeth Hansen Farmer, Einar Haukås, Kari Lenita Falck Moore, Tatjana Tratš, Claire Albrecht, Diptendu Santra, Pavel Smirnov, Margaret Doyle, Kathleen S Gray, Fredrik Schjesvold
Journal: Blood
Blood (2024) 144 (Supplement 1): 7016.
https://doi.org/10.1182/blood-2024-203364
Published: 2024
Journal Articles

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study

Niels WCJ Van De Donk, Homer Adams, III, Greet Vanhoof, Jakub Krejcik, MD, Koen Van der Borght, Tineke Casneuf, PhD, Tina Smets, Amy Axel, Yann Abraham, Hugo Ceulmans, Frederik Stevenaert, Saad Z Usmani, MD, Torben Plesner, MD, Sagar Lonial, MD, Berris van Kessel-Welmers, Henk M Lokhorst, Tuna Mutis, PhD, Nizar J. Bahlis, MD, Jordan Schecter, Christopher Chiu, Hervé Avet-Loiseau, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3124.
https://doi.org/10.1182/blood.V130.Suppl_1.3124.3124
Published: 2017
Journal Articles

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Homer Adams, III, PhD, Frederik Stevenaert, Jakub Krejcik, Koen Van der Borght, Tineke Casneuf, Tina Smets, Jaime Bald, Yann Abraham, Hugo Ceulemans, Greet Vanhoof, Tahamtan Ahmadi, MD, Saad Z Usmani, MD, Torben Plesner, Professor, Sagar Lonial, MD FACP, Berris van Kessel-Welmers, Henk M. Lokhorst, MD PhD, Tuna Mutis, MD PhD, Niels W.C.J. van de Donk, MD PhD, A. Kate Sasser
Journal: Blood
Blood (2016) 128 (22): 4521.
https://doi.org/10.1182/blood.V128.22.4521.4521
Published: 2016
Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Clinical Trials & Observations
Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary E. Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson
Journal: Blood
Blood (2016) 128 (14): 1821–1828.
https://doi.org/10.1182/blood-2016-07-726729
Published: 2016
Includes: Supplemental data
Journal Articles

Daratumumab depletes CD38 + immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W. C. J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser
Journal: Blood
Blood (2016) 128 (3): 384–394.
https://doi.org/10.1182/blood-2015-12-687749
Published: 2016
Includes: Supplemental data
Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Torben Plesner, MD, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, MD, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Howard Yeh, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson
Journal: Blood
Blood (2015) 126 (23): 507.
https://doi.org/10.1182/blood.V126.23.507.507
Published: 2015
Journal Articles

Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma

Jakub Krejcik, Tineke Casneuf, Inger Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, MD, Kevin Liu, Niels W.C.J. van de Donk, Brendan Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser
Journal: Blood
Blood (2015) 126 (23): 3037.
https://doi.org/10.1182/blood.V126.23.3037.3037
Published: 2015
Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 84.
https://doi.org/10.1182/blood.V124.21.84.84
Published: 2014
Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2013) 122 (21): 1986.
https://doi.org/10.1182/blood.V122.21.1986.1986
Published: 2013